

Sharing Rebates Can Save Americans with Diabetes \$500 Each Year and Improve Adherence, Especially for Black and Hispanic Americans

A new study by [GlobalData](#) looked at brand oral antidiabetic drugs (OADs) and found that sharing negotiated rebates directly with patients in commercial health plans can help lower costs, improve adherence and reduce health disparities.

Middlemen say they use rebates and discounts to lower monthly premiums, but sick patients shouldn't subsidize costs for the healthy. Sharing negotiated rebates directly with patients in commercial health plans taking brand oral antidiabetic drugs:

Lowers Costs	Save patients in the commercial market \$500+ annually on average	Reduce overall health care spending by \$8B over 10 years
Helps Patients Take Their Medicines as Prescribed	9% Average adherence improvement	Patients of color would see largest adherence improvements Hispanic patients: 16% Black patients: 11% Asian patients: 9% White patients: 8%
Saves Lives	Avoid nearly 700 premature deaths each year	Patients of color would see the highest reduction in mortality Hispanic patients: 6.7% Black patients: 4.9% Asian patients: 3.9% White patients: 3.4%

Over 10 years, sharing negotiated rebates directly with patients could reduce patient out-of-pocket spending by \$1.5B total

9.8% Reduction



Hispanic Population

6.2% Reduction



Black Population

7.1% Reduction



Asian Population

3.9% Reduction



White Population

Prior research also shows that better adherence to diabetes medicines is associated with:

**Improved
glycemic control**

**Lower risk of
disease-related
complications**

**Fewer hospitalizations
and visits to the
emergency department**

It's time for Congress to pass patient-centered solutions like sharing the savings. Doing so can improve health equity and affordability.

Learn more at phrma.org/cost.